Kaiser Permanente Northern California researchers say new as-needed PrEP regimen may increase use of the highly effective medication.
A recent article in The New York Times examines an that doctors can use to assess patient risk for H.I.V and recommend a daily pill to prevent infection – a strategy referred to as PrEP. The idea to use data from electronic health records to determine if patients are at high risk for H.I.V. infection was borne from researchers at Kaiser Permanente Division of Research in Northern California and Harvard.
An algorithm developed by Kaiser Permanente researchers in Northern California could refer more at-risk patients for the preventive medication PrEP.